VitruvianMD, a pioneering MedTech startup, has recently secured a substantial amount of $1.25 million (equivalent to approximately R23 million) in their Seed Extension II funding round.
The allocation of funds was led by 27four’s influential venture capital fund, The Nebula Fund, symbolizing a significant milestone for the company as it propels its groundbreaking technology forward.
By merging the disciplines of biomedical engineering and cutting-edge artificial intelligence (AI), VitruvianMD is effectuating a transformative impact on the domain of medical laboratories, thereby enhancing their accessibility.
VitruvianMD’s revolutionary technology centers around a sophisticated modular camera that seamlessly affixes to a wide array of microscopes, all while being propelled by cutting-edge artificial intelligence algorithms. This innovative technology facilitates the seamless transition of laboratories into a digital pathology framework.
In a global landscape plagued by a shortage of diagnosticians, particularly in regions like Sub-Saharan Africa where the ratio of pathologists to the population is concerning, the solutions offered by VitruvianMD possess the capacity to establish novel standards.
The pioneering methodology employed by VitruvianMD effectively tackles a significant quandary: the dearth of medical practitioners. The innovative solutions offered by the company possess the capacity to enhance accessibility to laboratories and their life-preserving capabilities in Sub-Saharan Africa.
Read also: Yunga, FlexiGyn win 2023 Africa prize for Engineering
Unlocking Collaborative Potential
This region currently suffers from a woefully inadequate pathologist-to-population ratio, standing at a mere one pathologist for every one million individuals, which is a mere fraction of the recommended threshold set forth by the esteemed World Health Organisation.
VitruvianMD eliminates geographical boundaries and reduces potentially life-threatening delays in diagnosis by merging their camera technology with user-friendly software in a way never before seen in the medical field. In addition, its AI platform allows doctors of varied levels of experience to analyse samples with more accuracy, speed up tests with greater consistency, and reduce mistakes.
A Revolutionary Effect
Significant inroads have been made by VitruvianMD’s AI technology in vital areas of medical. Haematologists use it to identify and categorise subsets of white blood cells. Screening for cervical cancer has become easier and more accurate with this advancement in histopathology. VitruvianMD is the first company to develop an AI-driven tool for assessing sperm quality for assisted reproduction, demonstrating the technology’s far-reaching impact on many facets of life. This new method not only determines whether sperm are viable, but also helps doctors choose the best ones to use when fertilising eggs.
“Tishanya Naidoo, Venture Capital Principal at 27four Investment Managers, emphasised how this groundbreaking technology seamlessly aligns with the Nebula Fund’s investment principles and standards,” Naidoo stated. The Nebula Fund, which was established in May 2023, has quickly acquired popularity due to its policy of giving top priority to investments in firms with rapid revenue growth and solid financial footing. The fund works in tandem with the Department of Science and Innovation to fill financing shortages for innovations and speed up the process of commercialising new technologies.
Fostering Disruptive Capability
Naidoo elaborated on the Nebula Fund’s strict investment criteria, which centre around identifying ventures showcasing disruptive potential, business-to-business solutions, proprietary intellectual property, rapid scalability across extensive markets, and resilient founding teams with industry-specific expertise. The fund puts a premium on making a noticeable difference in people’s lives.
Alternative Viewpoints
Naidoo emphasised the Nebula Fund’s ultimate objective of broadening its portfolio, despite the first investments’ focus on the healthcare sector. The fund will invest in SMEs providing revolutionary technology with the potential to significantly enhance people’s daily lives. The Nebula Fund is poised to make an impact on the landscape of impact-oriented businesses thanks to Naidoo’s leadership and the knowledge of 27four’s seasoned private markets team. Nebula Fund invests in early-stage companies that employ technology and creativity to solve societal concerns across industries, building on 27four’s record of strong returns and investments with a social impact.